- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04806893
Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction (LIBerate-HR)
Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Cardiovascular Disease, or at High Risk for Cardiovascular Disease, on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Randomized, double-blind, placebo-controlled, Phase 3 study of 52 weeks duration.
Patients who fulfill the inclusion and exclusion criteria will be enrolled at up to 65 sites in the United States, Canada, Europe, South Africa, Asia, Australasia, and the Middle East. Patients will be randomized in a 2:1 ratio to LIB003 or placebo. The total study duration will be up to 63 weeks which includes up to a Screening Period and 52 weeks of study drug treatment. Following randomization patients will be dosed and seen in the clinic Q4W (≤31 days).
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
New Delhi, India, 110002
- G.B. Pant Institute of Postgraduate Medical Education & Research
-
-
-
-
-
Jerusalem, Israel, 12000
- Department of Medicine, Hadassah University Hospital
-
Petah Tikva, Israel, 49100
- Rabin Medical Center, Beilinson Hospital,
-
-
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- The Lindner Research Center
-
Cincinnati, Ohio, United States, 45219
- Sterling Research Group
-
Cincinnati, Ohio, United States, 45227
- Metabolic & Atherosclerosis Research Center (MARC)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provision of written and signed informed consent prior to any study-specific procedure;
- Weight of ≥40 kg (88 lb) and body mass index (BMI) ≥17 and ≤42 kg/m2;
- History of CVD, (including cerebrovascular or peripheral arterial disease) or very-high risk for CVD as defined in the 2019 ESC/EAS Guidelines or
- High risk for CVD as defined in the 2019 ESC/EAS Guidelines
- At Screening or post Washout/Stabilization, LDL-C ≥70 mg/dL and TG ≤400 mg/dL while on stable lipid-lowering oral drug therapy (i.e., maximally tolerated statin with or without ezetimibe); Patients unable to tolerate approved doses of a statin may take lower than approved doses and dose less frequently than daily as long as the dose and dosing frequency is consistent; Patients with documentation of inability to tolerate any statin at any dose, or history of rhabdomyolysis, may also participate;
- Stable diet and lipid-lowering oral therapies (such as statins, ezetimibe, bile-acid sequestrants, OM-3 compounds, fenofibrate, bezafibrate, nicotinic acid, and bempedoic acid) or combinations thereof for at least 4 weeks
- Patients on a PCSK9 mAb at a dose of 75 mg, 140 mg, or 150 mg Q2W must undergo a washout period of ≥4 weeks after the last dose; for those on 300 mg or 420 mg Q4W (≤31 days) the washout period is ≥8 weeks following last dose;
- Females of childbearing potential must be using a highly effective form of birth control if sexually active and have a negative urine pregnancy test at the last Screening Visit;
Exclusion Criteria:
- Use of prohibited oral lipid-lowering agents mipomersen or lomitapide within 6 months of screening, gemfibrozil within 6 weeks of screening, apheresis within 2 months prior to randomization; received other investigational agent(s) such as PCSK9 or Lp(a) siRNA or locked nucleic acid-reducing agents within 12 months of the Screening Visit;
- Documented history of HoFH defined clinically or genetically
- History of any prior or active clinical condition or acute and/or unstable systemic disease compromising patient inclusion, at the discretion of the Investigator
- Females of childbearing potential who are sexually active, not using or unwilling to use a highly effective form of contraception, pregnant or breastfeeding, or who have a positive urine pregnancy test at the last Screening Visit;
- Moderate to severe renal dysfunction, defined as an eGFR <30 mL/min/1.73m2
- Active liver disease or hepatic dysfunction, history of liver transplant, and/or ALT or AST >2.5 × the ULN as determined by central laboratory analysis at screening
- Uncontrolled thyroid disease: hyperthyroidism or hypothyroidism
- Uncontrolled Type 1 or Type 2 DM, defined as FBS ≥200 mg/dL or HbA1C ≥9%;
- Uncontrolled serious cardiac arrhythmia, MI, unstable angina, PCI, CABG, placement of implantable cardioverter defibrillator or biventricular pacemaker, aortic valve surgery, or stroke within 3 months prior to the Screening Visit;
- Planned cardiac surgery or revascularization;
- New York Heart Association class III-IV heart failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LIB003 (lerodalcibep)
300 mg subcutaneously monthly (Q4W)
|
300 mg subcutaneous injection every month (Q4W)
Other Names:
|
Placebo Comparator: Placebo
matching placebo subcutaneously monthly (Q4W)
|
matching subcutaneous injection every month (Q4W)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LDL-C change compared to placebo
Time Frame: 52 weeks
|
Percent change in LS mean from baseline compared to placebo in LDL-C level
|
52 weeks
|
mean LDL-C change at week 50 and 52
Time Frame: 50 and 52 weeks
|
Percent change in LS mean from baseline compared to placebo in LDL-C level at Weeks 50 and 52
|
50 and 52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events as assessed by Medical Dictionary for Regulatory Activities as severe, moderate or mild after 52 weeks
Time Frame: 52 weeks
|
Evaluation of Adverse Events based on MedRA based on ITT population
|
52 weeks
|
Change in Free PCSK9
Time Frame: 52 weeks
|
Percent change in LS mean from baseline compared to placebo in free PCSK9
|
52 weeks
|
Percentage of patients achieving 2019 ESC/EAS LDL-C goals
Time Frame: 52 weeks
|
To assess the effects of LIB003 on the percentage of patients achieving an LDL-C <40 mg/dL, 55 mg/dL, <70 mg/dL, and 100 mg/dL
|
52 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Evan A Stein, MD PhD, LIB Therapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LIB003-006
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
-
Penn State UniversityAlmond Board of California; The Hershey CompanyCompletedCardiovascular DiseaseUnited States
Clinical Trials on lerodalcibep
-
LIB Therapeutics LLCMedpace, Inc.Enrolling by invitationFamilial Hypercholesterolemia | Elevated Cholesterol | Cardiovascular Disease With Mention of ArteriosclerosisUnited States, Israel, Norway, South Africa, Turkey, India
-
LIB Therapeutics LLCCompletedHypercholesterolemiaUnited States
-
LIB Therapeutics LLCMedpace, Inc.CompletedHeterozygous Familial HypercholesterolemiaUnited States, Israel, Norway, South Africa, Turkey
-
LIB Therapeutics LLCMedpace, Inc.Active, not recruitingHypercholesterolemia | Atherosclerotic Ischemic DiseaseSpain, Germany, France, Norway, United Kingdom
-
LIB Therapeutics LLCMedpace, Inc.Active, not recruitingCardiovascular Diseases | Hyper-LDL-cholesterolemiaUnited States
-
LIB Therapeutics LLCMedpace, Inc.CompletedHypercholesterolemiaUnited States
-
LIB Therapeutics LLCCompletedHomozygous Familial HypercholesterolemiaUnited States, Israel, Norway, South Africa, Turkey, India
-
LIB Therapeutics LLCCompletedCardiovascular Diseases | HypercholesterolemiaUnited States